首页> 外文期刊>Leukemia and lymphoma >Epidemiology, pathology and treatment of non-follicular indolent lymphomas.
【24h】

Epidemiology, pathology and treatment of non-follicular indolent lymphomas.

机译:非滤泡性惰性淋巴瘤的流行病学,病理学和治疗。

获取原文
获取原文并翻译 | 示例
       

摘要

Non-follicular indolent subtypes of non-Hodgkin lymphoma (NHL), which include chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL) and marginal zone lymphomas (MZL), are a diverse group of disorders with different presenting features, behaviour patterns and treatment outcomes. Current knowledge of these subtypes is largely based on retrospective analyses. A precise diagnosis can be difficult to achieve, and specific diagnostic criteria are needed to more precisely define some of the rarer indolent tumors, such as nodal and splenic MZLs. Although some subtypes of NHL have a prolonged indolent course, with a good prognosis (e.g. SLL), others (e.g. nodal and splenic MZLs) can rapidly evolve into more aggressive subtypes. In asymptomatic patients, treatment may be deferred until the disease progresses and the patient becomes symptomatic. Universally accepted therapeutic guidelines do not exist, however, and carefully designed, prospective clinical studies are needed to further assess optimal therapeutic approaches for these indolent NHLs.
机译:非霍奇金淋巴瘤(NHL)的非滤泡性惰性亚型,包括慢性淋巴细胞性白血病,小淋巴细胞性淋巴瘤(SLL)和边缘区淋巴瘤(MZL),是一组具有不同表现特征,行为模式和治疗结果的疾病。这些亚型的当前知识主要基于回顾性分析。精确的诊断可能难以实现,并且需要特定的诊断标准来更精确地定义一些罕见的惰性肿瘤,例如淋巴结和脾脏MZL。尽管NHL的某些亚型病程延长,预后良好(例如SLL),但其他一些亚型(例如淋巴结和脾脏MZL)可以迅速演变为更具侵略性的亚型。在无症状的患者中,治疗可以推迟到疾病进展并且患者有症状为止。但是,尚不存在普遍接受的治疗指南,需要精心设计的前瞻性临床研究才能进一步评估这些惰性NHL的最佳治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号